Articles

LCAR-B38M CAR-T Therapy Yields High Complete Response Rate and Survival Time
ASH 2019 – Multiple Myeloma
Almost 90% of patients responded to infusions of the LCAR B38M, and the majority of complete responders became minimal residual disease–negative. Read More ›
GRIFFIN Study: Daratumumab Deepens Responses Over Time
ASH 2019 – Multiple Myeloma
Newly diagnosed patients receiving daratumumab/lenalidomide/dexamethasone achieved rapid and deep responses. Read More ›
Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma
ASH 2019 – Multiple Myeloma
Positron emission tomography combined with computed tomography (PET/CT)/minimal residual disease–negativity concordance could be a predictive surrogate for patient outcomes. Read More ›
Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial
ASH 2019 – Multiple Myeloma
For the first time, overall survival benefit of adding daratumumab to standard of care in newly diagnosed, transplant-ineligible multiple myeloma patients is confirmed. Read More ›

Page 78 of 147


© Amplity, Inc. All Rights Reserved. Privacy Policy